Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+41-61-3241111
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Novartis (VTX:NOVN) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the VTX under the ticker symbol "NOVN."
What price target have analysts set for NOVN?
19 Wall Street analysts have issued 12-month price objectives for Novartis' stock. Their forecasts range from CHF 75 to CHF 110. On average, they expect Novartis' share price to reach CHF 91.32 in the next twelve months. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
Press coverage about NOVN stock has trended somewhat positive on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Axovant Sciences (AXGT), Biocure Technology (CURE) and Biotest (BIO).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
- Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
- Mr. Andrew Novak, VP & Chief Accounting Officer
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.
MarketBeat Community Rating for Novartis (VTX NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
